MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, AVBP had $16,563K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$16,563K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Sales and maturities of short-te...
    • Proceeds from issuance of common...
    • Stock-based compensation expense
    • Others
Negative Cash Flow Breakdown
    • Purchase of short-term and long-...
    • Accrued expenses
    • Prepaid expenses and other curre...
    • Amortization/accretion of bond d...

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-43,320 -35,544 -34,978 -95,786
Stock-based compensation expense
5,485 3,222 3,716 5,582
Amortization/accretion of bond discounts/premiums
-559 -3,026 --
Prepaid expenses and other current assets
2,561 -275 6,490 6,346
Other assets
-37 ---
Accounts payable
2,807 -8 1,869 280
Accrued expenses
-3,828 4,428 91 2,148
Operating lease liabilities
47 -5 -6 -10
Net cash used in operating activities
-41,892 -30,658 -35,798 -94,132
Purchase of short-term and long-term investments
64,383 151,180 90,369 31,385
Sales and maturities of short-term and long-term investments
67,965 79,981 39,609 82,116
Net cash used in investing activities
3,582 -71,199 -50,760 50,731
Proceeds from issuance of common stock, net of issuance costs
54,724 34,658 167,973 -
Proceeds from the exercise of stock options
149 84 49 369
Payment of deferred financing costs
-17 -300 353
Proceeds from issuance of common stock in an initial public offering and atm facility, net of issuance costs
---81,857
Net cash provided by financing activities
54,873 34,725 86,465 81,873
Net increase (decrease) in cash and cash equivalents
16,563 -67,132 -93 38,472
Cash and cash equivalents at beginning of the year
45,540 112,672 74,293 -
Cash and cash equivalents at end of the year
62,103 45,540 112,672 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon stock, net of...$54,724K Proceeds from theexercise of stock options$149K Sales and maturitiesof short-term and...$67,965K Net cash provided byfinancing activities$54,873K Net cash used ininvesting activities$3,582K Canceled cashflow$64,383K Net increase(decrease) in cash and cash...$16,563K Canceled cashflow$41,892K Stock-based compensationexpense$5,485K Accounts payable$2,807K Operating leaseliabilities$47K Other assets-$37K Purchase of short-termand long-term...$64,383K Net cash used inoperating activities-$41,892K Canceled cashflow$8,376K Net loss-$43,320K Accrued expenses-$3,828K Prepaid expenses andother current assets$2,561K Amortization/accretion of bonddiscounts/premiums-$559K

ArriVent BioPharma, Inc. (AVBP)

ArriVent BioPharma, Inc. (AVBP)